Last reviewed · How we verify

Ropivacaine 2 %

Hospital Ambroise Paré Paris · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameRopivacaine 2 %
SponsorHospital Ambroise Paré Paris
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and transmission of nerve impulses. This results in local anesthesia in the area where it is administered. It is an amide-type local anesthetic with a long duration of action and lower cardiotoxicity compared to some other local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: